Recro Pharma receives Complete Response Letter from FDA for intravenous meloxicam
Recro Pharma announced it has received a second CRL from the FDA regarding their NDA seeking approval for IV meloxicam for the management of moderate to severe pain. The FDA’s comments in the CRL noted that the delayed onset fails to meet the prescriber expectations for intravenous drugs. March 22, 2019